曲妥珠单抗联合胸腺肽α1治疗老年晚期胃癌疗效以及对肿瘤标志物、糖类抗原的影响

Trastuzumab Combined with Thymosinα1 in the Treatment of Senile Advanced Gastric Cancer,and the Effect of Tumor Markers and Carbohydrate Antigen

目的:研究曲妥珠单抗联合胸腺肽α1应用于老年晚期胃癌治疗中的效果及对肿瘤标志物、糖类抗原的影响。方法:选取2017年1月—2022年1月样本医院收治的80例胃癌晚期老年患者作为研究对象,按照双盲法将其分为对照组和观察组,每组各40例。两组患者均予以化疗治疗,对照组静注曲妥珠单抗治疗,观察组在对照组的基础上联合注射胸腺肽α1治疗,比较两组患者疗效、生存期、肿瘤标志物变化、糖类抗原变化及不良反应发生情况。结果:治疗后,观察组治疗总有效率高于对照组,差异有统计学意义(χ^(2)=7.324,P<0.05);治疗后,观察组3年、5年的生存率均高于对照组,差异有统计学意义(χ^(2)=9.899、12.288,P<0.05),而两组患者1年的生存率,差异无统计学意义(χ^(2)=1.726,P>0.05);观察组癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)水平低于对照组,差异有统计学意义(t=2.564、5.346、4.028,P<0.05);治疗后,观察组不良反应发生率明显低于对照组,差异有统计学意义(χ^(2)=4.053,P<0.05)。结论:曲妥珠单抗联合胸腺肽α1应用于老年晚期胃癌治疗疗效良好,对生存期及肿瘤标志物具有良好影响,且安全性高。

Objective:To study the effect of thymosinα1 combined with trastuzumab in the treatment of elderly patients with advanced gastric cancer and its effect on the expression of serum tumor markers.Methods:80 elderly patients with advanced gastric cancer who were admitted to the hospital from January 2017 to January 2022 were selected and divided into two groups according to the double-blind method,with 40 cases in each group.Both groups were treated with chemotherapy,the control group was treated with intravenous trastuzumab,and the observation group was treated with thymosinα1 on the basis of the control group.The efficacy,survival time,tumor marker changes,carbohydrate antigen changes and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of control group was lower than that of observation group(χ^(2)=7.324,P<0.05).After treatment,the 3-year and 5-year survival rates of the observation group were higher than those of the control group,and the difference was statistically significant(χ^(2)=9.899,12.288;P<0.05),while the 1-year survival rates of the two groups were not statistically significant(χ^(2)=1.726,P>0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 125(CA125)in observation group were lower than those in control group,and the differences were statistically significant(t=2.564,5.346,4.028;P<0.05).After treatment,the incidence of adverse reactions in observation group was significantly lower than that in control group,and the difference was statistically significant(χ^(2)=4.053,P<0.05).Conclusion:Thymosinα1 combined with trastuzumab has good effect on postoperative survival and tumor markers in elderly gastric cancer,with high safety.